Tufts-CEVR HEOR Leaders Survey

How will HEOR leaders respond to recent policy changes? A survey from Tufts and the Center for the Evaluation of Value and Risk in Health (CEVR) provides the answer. About 2/3 of the n=57 respondents were Head of their HEOR department and the remaining 1/3 had some other senior level HEOR role. Three key topic…

Read More

Startup Booster Therapeutics Launches to Usher In Next Wave of Protein-Degrading Drugs

Booster Therapeutics’ small molecules activate the 20S proteasome, a component of cells that gets rid of misfolded proteins. Parkinson’s and Alzheimer’s are potential disease targets for the startup, which launched with $15 million in seed financing. The post Startup Booster Therapeutics Launches to Usher In Next Wave of Protein-Degrading Drugs appeared first on MedCity News.

Read More